{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:46:31Z","timestamp":1776347191210,"version":"3.51.2"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jdcr.2022.04.019","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T21:49:03Z","timestamp":1651700943000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality"],"prefix":"10.1016","volume":"24","author":[{"given":"Akshay","family":"Flora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.jdcr.2022.04.019_bib1","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jdcr.2022.04.019_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5S","key":"10.1016\/j.jdcr.2022.04.019_bib3","first-page":"18","article-title":"Psoriasis risk factors and triggers","volume":"102","author":"Lee","year":"2018","journal-title":"Cutis"},{"issue":"7","key":"10.1016\/j.jdcr.2022.04.019_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4568","article-title":"SARS-CoV-2 and guttate psoriasis: a case report and review of literature","volume":"9","author":"Ali","year":"2021","journal-title":"Clin Case Rep"},{"issue":"5","key":"10.1016\/j.jdcr.2022.04.019_bib5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jdcr.2017.06.015","article-title":"Ustekinumab-induced remission of recalcitrant guttate psoriasis: a case series","volume":"3","author":"Brummer","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.jdcr.2022.04.019_bib6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1346-8138.2010.00871.x","article-title":"Clinical course of guttate psoriasis: long-term follow-up study","volume":"37","author":"Ko","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdcr.2022.04.019_bib7","doi-asserted-by":"crossref","first-page":"652191","DOI":"10.3389\/fimmu.2021.652191","article-title":"Resident memory T cells in autoimmune skin diseases","volume":"12","author":"Ryan","year":"2021","journal-title":"Front Immunol"},{"issue":"1 suppl 1","key":"10.1016\/j.jdcr.2022.04.019_bib8","article-title":"IL-23 maintains tissue resident memory Th17 cells in murine and psoriatic skin","volume":"206","author":"Whitley","year":"2021","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jdcr.2022.04.019_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bjd.12960","article-title":"Guttate psoriasis is associated with an intermediate phenotype of impaired Langerhans cell migration","volume":"171","author":"Eaton","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2022.04.019_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"issue":"3","key":"10.1016\/j.jdcr.2022.04.019_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"S3","key":"10.1016\/j.jdcr.2022.04.019_bib12","first-page":"12","article-title":"Identification of clinical and biomarker parameters associated with long-term maintenance of PASI 90 response following guselkumab treatment withdrawal in psoriasis","volume":"33","author":"Liu","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jdcr.2022.04.019_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.jdcr.2022.04.019_bib14","first-page":"822","article-title":"Resolution of guttate psoriasis plaques after one-time administration of guselkumab","volume":"18","author":"Hall","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2022.04.019_bib15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/ijd.15478","article-title":"Durable remissions of guttate psoriasis following short courses of IL-17 inhibitors","volume":"60","author":"Printy","year":"2021","journal-title":"Int J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622001989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622001989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:26Z","timestamp":1762475066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622001989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":15,"alternative-id":["S2352512622001989"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.04.019","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}